Carl Zeiss Meditec closes financial year on a high
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ Revenue increases by 6.6% in financial year 2008/2009 - EBIT marginclimbs to 11.9% - Operative cash flow up by 60%(Jena, 14 December 2009) The medical technology provider Carl ZeissMeditec closed its financial year (end: 30 September 2009) on a high.In spite of difficult general conditions, the Company increased itsrevenue and earnings. The Company's excellence programme RACE 2010,which was implemented in summer 2008, was an important driver of thispositive trend.Carl Zeiss Meditec generated consolidated revenue of EUR 640.1million in financial year 2008/2009, compared with EUR 600.1 millionthe previous year. Earnings before interest and tax (EBIT) increasedby 11.5% in the reporting period to EUR 76.1 million (previous year:EUR 68.2 million). The EBIT margin increased accordingly, from 11.4%in the previous year to 11.9% in financial year 2008/2009. Cash flowfrom operating activities rose by as much as 60% to EUR 87.4 million.The results achieved in financial year 2008/2009 thus validate theCompany's policy of focusing on sustainable growth. The SupervisoryBoard and Management Board shall therefore propose to the AnnualGeneral Meeting 2010 a dividend of EUR 0.18."I would like to thank in particular our dedicated and competentemployees around the world, without whose ideas and extraordinarycommitment this successful financial year would not have beenpossible. Many of our customers are impressed to see the passion withwhich our employees work day after day to find solutions for thehospital and medical practice environment," says Dr. Michael Kaschke,President and CEO of Carl Zeiss Meditec AG.Regionally, the Company achieved its highest growth rates in the"Asia/Pacific" region in financial year 2008/2009, where growth was21.1%. The "Americas" region continues to account for the largestshare of revenue, generating 35.6%.The strategic business units Ophthalmic Systems and Microsurgeryincreased their revenue in financial year 2008/2009 by 9.0% and 3.8%,respectively. The strength of the US dollar and the Japanese yenagainst the euro had a positive effect on both these business unitsin the first half of the year. Revenue in the Surgical OphthalmologySBU grew by 6.8%.Dr. Michael Kaschke explains: "This growth also highlights that weused the last year successfully to fully integrate our acquiredunits. This was an important step, as it is only after integrationthat the full value of acquisitions can be realised. Carl ZeissMeditec is now ready for new opportunities and is actively searchingfor them."The Company's equity ratio was 71.6% as of 30 September 2009 (30September 2008: 70.0%). Net cash amounted to EUR 252.0 million at theend of the financial year (30 September 2008: EUR 210.4 million)."Our professed aim is to achieve sustainable, profitable growth. Weare continuously working towards this goal with our RACE 2010programme. We expect revenue growth in financial year 2009/2010 toagain be at least on a par with market growth. We aim to at leastmaintain our already very good operating profitability (EBIT margin),without foregoing necessary investments, in order to ensurecontinuous growth in value-added for the Company," emphasised Dr.Kaschke.Revenue by strategic business unitFigures in EUR '000: Financial year 2007/2008 / Financial year2008/2009 / Change from previous yearOphthalmic Systems / 285,010 / 310,788 / 9.0%Surgical Ophthalmology / 73,990 / 79,036 / 6.8%Microsurgery / 241,190 / 250,265 / 3.8%Revenue by regionFigures in EUR '000: Financial year 2007/2008 / Financial year2008/2009 / Change from previous yearGermany / 54,797 / 56,413 / 2.9%EMEA / 194,105 / 188,320 / -3.0%Americas / 212,767 / 227,674 / 7.0%Asia / Pacific / 138,522 / 167,682 / 21.1% --- End of Message ---Carl Zeiss Meditec AGGoeschwitzer Strasse 51-52 Jena GermanyWKN: 531370; ISIN: DE0005313704; Index: Prime All Share, TECH All Share, TecDAX;Listed: Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Prime Standard in Frankfurter Wertpapierbörse, Regulierter Markt in Frankfurter Wertpapierbörse;
Datum: 14.12.2009 - 07:09 Uhr
Sprache: Deutsch
News-ID 9559
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 452 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Carl Zeiss Meditec closes financial year on a high"
steht unter der journalistisch-redaktionellen Verantwortung von
Carl Zeiss Meditec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
